VanEck Associates’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15K | Hold |
1,270
| – | – | ﹤0.01% | 1366 |
|
|
2025
Q1 | $11K | Hold |
1,270
| – | – | ﹤0.01% | 1358 |
|
|
2024
Q4 | $18K | Sell |
1,270
-114
| -8% | -$1.62K | ﹤0.01% | 1343 |
|
|
2024
Q3 | $21K | Sell |
1,384
-738
| -35% | -$11.2K | ﹤0.01% | 1312 |
|
|
2024
Q2 | $41K | Sell |
2,122
-111
| -5% | -$2.15K | ﹤0.01% | 1301 |
|
|
2024
Q1 | $84K | Buy |
2,233
+325
| +17% | +$12.2K | ﹤0.01% | 1244 |
|
|
2023
Q4 | $107K | Buy |
1,908
+362
| +23% | +$20.3K | ﹤0.01% | 1231 |
|
|
2023
Q3 | $64K | Buy |
1,546
+125
| +9% | +$5.18K | ﹤0.01% | 1262 |
|
|
2023
Q2 | $79K | Sell |
1,421
-211
| -13% | -$11.7K | ﹤0.01% | 1266 |
|
|
2023
Q1 | $91K | Buy |
1,632
+107
| +7% | +$5.97K | ﹤0.01% | 1248 |
|
|
2022
Q4 | $56K | Buy |
1,525
+200
| +15% | +$7.34K | ﹤0.01% | 1305 |
|
|
2022
Q3 | $38K | Sell |
1,325
-86,854
| -98% | -$2.49M | ﹤0.01% | 1284 |
|
|
2022
Q2 | $3.99M | Buy |
88,179
+9,124
| +12% | +$413K | 0.01% | 516 |
|
|
2022
Q1 | $6.01M | Buy |
79,055
+16,364
| +26% | +$1.24M | 0.01% | 469 |
|
|
2021
Q4 | $9.34M | Sell |
62,691
-2,091
| -3% | -$311K | 0.02% | 387 |
|
|
2021
Q3 | $9.43M | Sell |
64,782
-19,701
| -23% | -$2.87M | 0.02% | 353 |
|
|
2021
Q2 | $16.5M | Sell |
84,483
-6,798
| -7% | -$1.33M | 0.04% | 277 |
|
|
2021
Q1 | $16.5M | Buy |
+91,281
| New | +$16.5M | 0.04% | 256 |
|